HIGHLIGHTS
- who: N- and colleagues from the , Paris, France of, University Tübingen, Tübingen, Germany have published the research: Pimasertib Versus Dacarbazine in Patients With Melanoma: Phase II Randomized Controlled Trial with Crossover, in the Journal: (JOURNAL) of 04/07/2015
- what: This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated Phase II multicenter Cancers 2020 12 1727; __NEWPAGE__Cancers 2020 12 1727 2 of 11 open-label trial. The aim of the trial was achieved; progression-free survival (PFS) was significantly improved in the pimasertib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.